Phibro Animal Health Q2 EPS 26.1% Above Estimates on $373.9M Revenue Beat
Phibro Animal Health reported Q2 adjusted EPS of $0.87, 26.1% above estimates, on revenues of $373.9 million, 4.7% higher than forecast. The company’s estimated long-term earnings growth rate of 21.5% outpaces the industry’s 12.5%, reflecting consistent quarter-over-quarter surprise averaging 20.1%.
1. Q2 Financial Results
Phibro Animal Health delivered adjusted EPS of $0.87 for fiscal Q2, exceeding consensus by 26.1%, alongside revenues of $373.9 million, a 4.7% beat. This marks the fourth consecutive quarter of earnings outperformance, underscoring strong operational execution and pricing power across its animal health product lines.
2. Growth Outlook and Industry Positioning
The company projects a long-term earnings growth rate of 21.5%, nearly double the industry average of 12.5%, driven by expanding feed additives and vaccines portfolios. Historical surprise rates averaging 20.1% highlight robust forecast accuracy and suggest upward potential for guidance revisions.